Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV
· Real-Time Price · USD
1.82
0.04 (2.25%)
At close: Aug 15, 2025, 3:59 PM
1.91
4.95%
After-hours: Aug 15, 2025, 07:55 PM EDT
Enlivex Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 90K | 36K | 161K | 160K | 188K | 200K | 214K | 212K | 209K | 221K | 192K | 176K | 188K | 150K | 157K | 122K | 117K |
Gross Profit | -90K | -36K | -161K | -160K | -188K | -200K | -214K | -212K | -209K | -221K | -192K | -176K | -188K | -150K | -157K | -122K | -117K |
Operating Income | -3.53M | -5.63M | -3.12M | -2.99M | -3.95M | -6.09M | -5.63M | -6.65M | -6.78M | -7.84M | -5.68M | -5.87M | -6.4M | -7.81M | -3.86M | -3.81M | -3.8M |
Interest Income | 81K | 456K | n/a | n/a | 11K | n/a | n/a | 422.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -3.45M | -5.18M | -2.6M | -3.1M | -4.14M | -9.1M | -5.96M | -6.79M | -7.22M | -7.19M | -5.73M | -9.91M | -8.22M | -4.74M | -3.42M | -3.11M | -3.2M |
Net Income | -3.45M | -5.18M | -2.6M | -3.1M | -4.14M | -9.1M | -5.96M | -6.79M | -7.22M | -7.19M | -5.73M | -9.91M | -8.22M | -4.74M | -3.42M | -3.11M | -3.2M |
Selling & General & Admin | 954K | 1.96M | 771K | 987K | 1.09M | 733K | 1.28M | 1.61M | 1.61M | 1.74M | 1.48M | 1.76M | 1.72M | 2.48M | 1.19M | 1.27M | 1.3M |
Research & Development | 2.55M | 3.42M | 2.35M | 2M | 2.86M | 4.45M | 4.35M | 5.04M | 5.18M | 5.7M | 4.2M | 4.11M | 4.68M | 5.17M | 2.68M | 2.54M | 2.5M |
Other Expenses | 29K | 256K | n/a | n/a | n/a | n/a | -335K | -143K | -435K | 402K | -56K | -4.04M | -1.82M | 167K | 440K | 700K | 602K |
Operating Expenses | 3.53M | 5.63M | 3.12M | 2.99M | 3.76M | 5.89M | 5.63M | 6.65M | 6.78M | 7.84M | 5.68M | 5.87M | 6.4M | 7.81M | 3.86M | 3.81M | 3.8M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 435K | n/a | 56K | 4.04M | 1.82M | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 3.5M | 5.48M | 3.12M | 2.99M | 3.95M | 6.09M | n/a | 6.65M | 6.78M | 7.84M | 5.68M | 5.87M | 6.4M | 7.81M | 3.86M | 3.81M | 3.8M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | 156.19K | n/a | n/a | n/a | n/a | 56K | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 21.9M | 21.9M | 21.28M | 19.55M | 18.73M | 18.6M | 18.6M | 18.58M | 18.52M | 18.42M | 18.39M | 18.38M | 18.37M | 18.31M | 18.31M | 18.31M | 16.48M |
Shares Outstanding (Diluted) | 21.9M | 21.9M | 21.28M | 19.55M | 18.73M | 18.6M | 18.6M | 18.58M | 18.52M | 18.42M | 18.39M | 18.38M | 18.37M | 18.31M | 18.31M | 18.31M | 16.48M |
EPS (Basic) | -0.16 | -0.24 | -0.12 | -0.16 | -0.22 | -0.49 | -0.32 | -0.37 | -0.41 | -0.35 | -0.31 | -0.76 | -0.55 | -0.26 | -0.19 | -0.17 | -0.19 |
EPS (Diluted) | -0.16 | -0.24 | -0.12 | -0.16 | -0.22 | -0.49 | -0.32 | -0.37 | -0.41 | -0.35 | -0.31 | -0.76 | -0.55 | -0.26 | -0.19 | -0.17 | -0.19 |
EBITDA | -3.41M | -5.14M | -2.96M | -2.83M | -3.76M | -5.89M | -5.41M | -6.44M | -6.57M | -7.62M | -5.49M | -5.7M | -6.22M | -7.66M | -3.71M | -3.69M | -3.69M |
EBIT | -3.5M | -5.18M | -3.12M | -2.99M | -3.95M | -6.09M | -5.63M | -6.65M | -6.78M | -7.84M | -5.68M | -5.87M | -6.4M | -7.81M | -3.86M | -3.81M | -3.8M |
Depreciation & Amortization | 90K | 36K | 161K | 160K | 188K | 200K | 214K | 212K | 209K | 221K | 192K | 176K | 188K | 150K | 157K | 122K | 117K |